MWNA
HBIO icon

Marshall Wace North America’s Harvard Bioscience HBIO Stock Holding History

Marshall Wace North America’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-241
Closed -$7K – 1405
2019
Q3 		$7K Buy
+241
New +$5.99K ﹤0.01% 1270

Other funds holding HBIO

ECM
Engine Capital Management New York $828M AUM 6.49% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
DGHMC
Dalton, Greiner, Hartman, Maher & Co New York $126M AUM 92.88% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
HP
Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

Marshall Wace North America's HBIO Position: Q4 2019 in Review

Marshall Wace North America sold out of Harvard Bioscience (HBIO) in Q4 2019, closing a stake of 241 shares — an estimated $7K sold.

Marshall Wace North America first reported a position in HBIO in Q3 2019 and held it in 1 quarter. The position peaked at $7K in Q3 2019. 68 funds tracked by Wall St. Rank hold HBIO as of Q4 2019.

  • Marshall Wace North America reported no remaining Harvard Bioscience position as of Q4 2019 after selling out during the quarter.
  • Marshall Wace North America sold 241 Harvard Bioscience shares in Q4 2019, an estimated $7K.
  • Marshall Wace North America first reported a position in Harvard Bioscience in Q3 2019 and held it in 1 quarter.
  • Marshall Wace North America's Harvard Bioscience position peaked at $7K in Q3 2019.
  • 68 funds tracked by Wall St. Rank held Harvard Bioscience as of Q4 2019.

Based on Marshall Wace North America's 13F filing for Q4 2019, filed 14 Feb 2020.